LY3372689 (Oglemilide)

Migration, Crosslink

📖

LY3372689 (Oglemilide)

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-ly3372689

📖 Wiki Page

therapeutic2234 wordssynced 2026-04-02

LY3372689 (Oglemilide)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">LY3372689 (Oglemilide)</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Population</td>
</tr>
<tr>
<td class="label">NCT04640909</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">NCT04744030</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">NCT05097339</td>
<td>Early AD patients</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">LY3372689</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">ASN90</td>
<td>Asceneuron</td>
</tr>
<tr>
<td class="label">MK-8719</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">LOBLD</td>
<td>Lundbeck</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>>60%</td>
</tr>
<tr>
<td class="label">Brain-to-plasma ratio</td>
<td>~0.5</td>
</tr>
<tr>
<td class="label">Cmax</td>
<td>2-4 hours post-dose</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>8-12 hours</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td><30%</td>
</tr>
<tr>
<td class="label">Site</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Thr181</td>
<td>GSK-3β, CDK5</td>
</tr>
<tr>
<td class="label">Thr231</td>
<td>GSK-3β</td>
</tr>
<tr>
<td class="label">Ser396</td>
<td>GSK-3β</td>
</tr>

...

LY3372689 (Oglemilide)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">LY3372689 (Oglemilide)</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Population</td>
</tr>
<tr>
<td class="label">NCT04640909</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">NCT04744030</td>
<td>Healthy volunteers</td>
</tr>
<tr>
<td class="label">NCT05097339</td>
<td>Early AD patients</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">LY3372689</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">ASN90</td>
<td>Asceneuron</td>
</tr>
<tr>
<td class="label">MK-8719</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">LOBLD</td>
<td>Lundbeck</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>>60%</td>
</tr>
<tr>
<td class="label">Brain-to-plasma ratio</td>
<td>~0.5</td>
</tr>
<tr>
<td class="label">Cmax</td>
<td>2-4 hours post-dose</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>8-12 hours</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td><30%</td>
</tr>
<tr>
<td class="label">Site</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Thr181</td>
<td>GSK-3β, CDK5</td>
</tr>
<tr>
<td class="label">Thr231</td>
<td>GSK-3β</td>
</tr>
<tr>
<td class="label">Ser396</td>
<td>GSK-3β</td>
</tr>
<tr>
<td class="label">Ser404</td>
<td>GSK-3β</td>
</tr>
<tr>
<td class="label">Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>15-20%</td>
</tr>
<tr>
<td class="label">Diarrhea</td>
<td>10-15%</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>10%</td>
</tr>
<tr>
<td class="label">Fatigue</td>
<td>5-10%</td>
</tr>
</table>

LY3372689 (also known as oglemilide) is a potent small-molecule O-GlcNAcase (OGA) inhibitor developed by Eli Lilly for the treatment of Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and other tauopathies[@oga][@phase]. It represents a novel disease-modifying approach targeting tau pathology through modulation of tau post-translational modifications, specifically O-GlcNAcylation. Unlike antibody-based therapies that aim to clear existing tau aggregates, OGA inhibitors like LY3372689 work upstream by preventing tau hyperphosphorylation and subsequent aggregation, potentially providing therapeutic benefits before significant tau pathology has accumulated[@yuzwa2012][@kim2013].

The O-GlcNAcylation of proteins is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to serine and threonine residues. This modification is regulated by two enzymes: O-GlcNAc transferase (OGT), which adds the modification, and O-GlcNAcase (OGA, also known as MGEA5), which removes it[@hart2014]. In the brain, O-GlcNAcylation plays crucial roles in neuronal function, synaptic plasticity, and protein homeostasis. Importantly, tau protein is heavily modified by O-GlcNAc, and this modification competes with pathogenic phosphorylation at many of the same sites[@liu2019].

Molecular Biology of O-GlcNAcylation

O-GlcNAcase Structure and Function

The O-GlcNAcase enzyme (MGEA5) is a 916-amino acid protein with two functional domains: a catalytic domain that hydrolyzes O-GlcNAc modifications and a Stackin domain involved in protein-protein interactions. The enzyme is expressed throughout the brain, with high expression in neurons and glia. OGA is localized to the cytoplasm and nucleus, where it regulates O-GlcNAcylation of numerous nuclear and cytoplasmic proteins[@warner2015].

OGA expression is altered in Alzheimer's disease and other tauopathies. Studies have shown increased OGA expression in AD brain tissue, particularly in regions affected by neurofibrillary tangles. This increased OGA activity may contribute to reduced tau O-GlcNAcylation, promoting tau hyperphosphorylation and aggregation. The balance between OGT and OGA activity (the O-GlcNAc "cycle") is therefore critical for tau pathology development[@liu2019].

Tau O-GlcNAcylation Sites

Tau protein contains over 50 serine and threonine residues that can be modified by O-GlcNAc. Key O-GlcNAcylation sites include Ser262, Ser356, Thr231, and Ser409. Importantly, many of these same residues are sites of pathological phosphorylation in AD and related disorders. The mutually exclusive nature of O-GlcNAcylation and phosphorylation provides the mechanistic basis for OGA inhibitor therapy[@yuzwa2012][@chen2020].

Structural studies have demonstrated that O-GlcNAc modification at specific tau residues stabilizes the protein in a conformation less prone to phosphorylation by GSK3β and CDK5, the primary tau kinases. Additionally, O-GlcNAcylation reduces tau's ability to form insoluble aggregates by inhibiting the nucleation step of aggregation[@bachran2020].

Mechanism of Action

Primary Mechanism

LY3372689 works by inhibiting O-GlcNAcase, the enzyme responsible for removing O-GlcNAc modifications from tau protein[@oga][@phase]. When OGA is inhibited:

Increased Tau O-GlcNAcylation: More tau proteins carry O-GlcNAc modifications at key sites

Competitive Inhibition of Phosphorylation: O-GlcNAc and phosphate groups compete for the same serine/threonine residues. When a site is O-GlcNAcylated, it cannot be phosphorylated[@yuzwa2012]

Reduced Phospho-tau Formation: Phosphorylation at key pathological sites (Thr181, Ser202, Thr205, Ser396, Ser404) is reduced

Protection Against Aggregation: O-GlcNAcylated tau is less prone to form toxic oligomers and fibrils[@sandoval2021]

Downstream Effects

Beyond direct effects on tau, OGA inhibition affects multiple cellular pathways:

GSK3β modulation: O-GlcNAcylation of GSK3β inhibits its kinase activity, reducing tau phosphorylation cascade
Synaptic protein protection: O-GlcNAc modification protects synaptic proteins from pathological changes[@horton2020]
Mitochondrial function: O-GlcNAcylation supports mitochondrial health and energy metabolism in neurons[@lee2025]
Neuroinflammation: OGA inhibition reduces glial activation and pro-inflammatory cytokine production[@west2023]

Biological Rationale

The rationale for OGA inhibition in tauopathies is supported by extensive preclinical evidence:

Animal Model Studies

In mouse models of tauopathy (e.g., hTauP301S, rTg4510), OGA inhibitors including Thiamet-G and related compounds have demonstrated:

Reduced tau phosphorylation at multiple sites
Decreased insoluble tau accumulation
Improved behavioral performance
Reduced neuroinflammation
Preservation of synaptic markers[@mueller2018][@davies2024]

Human Post-Mortem Studies

Analyses of AD brain tissue have revealed:

Altered OGA expression in affected regions
Reduced global O-GlcNAcylation in AD brains
Correlation between O-GlcNAc levels and cognitive scores
O-GlcNAc inversely correlated with neurofibrillary tangle burden[@warner2015][@zhao2025]

Genetic Evidence

Genetic studies have identified OGA variants associated with:

Altered AD risk in genome-wide association studies
Modulation of age of onset
Interaction with known AD risk genes[@zhao2025]

Preclinical Development

Discovery and Optimization

LY3372689 emerged from Eli Lilly's drug discovery program targeting O-GlcNAcase:

Lead optimization: Iterative SAR (structure-activity relationship) studies to improve potency and brain penetration
Selectivity profiling: Extensive profiling against related enzymes including hexosaminidases
Pharmacokinetic optimization: Formulation development for oral bioavailability

In Vitro Pharmacology

Preclinical studies demonstrated:

Potency: Nanomolar inhibition of human OGA (IC50 ~5 nM)
Selectivity: >100-fold selectivity over hexosaminidase A and B
Cellular activity: Increased O-GlcNAcylation in neurons at concentrations <100 nM
Tau protection: Reduced tau phosphorylation at pathological sites in cell models

In Vivo Efficacy

Animal studies in tauopathy mouse models showed:

Dose-dependent brain O-GlcNAc elevation
Reduced tau phosphorylation in cortex and hippocampus
Improved behavioral performance in memory tasks
Acceptable tolerability in chronic dosing studies

Clinical Development

Phase I Trial Design

The Phase I program comprised multiple studies:

Phase I Results

First-in-human studies evaluated the safety, tolerability, and pharmacokinetics of LY3372689 in healthy volunteers and patients with early Alzheimer's disease[@oga][@phase][@xiang2022]:

Target engagement: Dose-dependent increase in CSF O-GlcNAc levels confirming CNS target engagement
Pharmacokinetics: Suitable for once-daily oral dosing (T1/2 ~10 hours)
Safety profile: Generally well-tolerated with mild GI effects
Brain penetration: Demonstrated CSF drug levels consistent with BBB penetration

Phase II Development

LY3372689 advanced to Phase II in early Alzheimer's disease:

Study: NCT05097339
Population: Early AD (MCI due to AD, mild AD dementia)
Duration: 52 weeks treatment
Primary endpoints: Safety, tolerability
Secondary endpoints: CSF biomarkers, cognitive measures

Phase II Results

The Phase II trial completed in 2024[@phase][@peters2025]:

Biomarker results: Demonstrated dose-dependent CSF O-GlcNAc elevation
Tau biomarkers: Modest reductions in CSF p-tau181 observed
Cognitive outcomes: Did not meet primary cognitive endpoint
Safety: Well-tolerated with no unexpected safety signals

Biomarker Strategy

Clinical trials for LY3372689 employ comprehensive biomarker approaches[@kim2023][@mori2023]:

CSF O-GlcNAcylated Tau: Direct measurement of O-GlcNAcylation levels as proof of mechanism
CSF Phospho-tau: Measurement of phosphorylated tau species (p-tau181, p-tau217)
CSF Total Tau: Overall tau protein levels as neuronal injury marker
Tau PET Imaging: [^18F]flortaucipir for regional tau burden
Amyloid PET: For patient stratification and off-target effects
Neurodegeneration markers: NfL, NSE in CSF and blood

Advantages of Small-Molecule OGA Inhibitors

Compared to antibody-based tau immunotherapies, OGA inhibitors offer several potential advantages[@yang2021]:

Oral Bioavailability: Small molecules can be delivered orally, improving patient convenience and adherence

Blood-Brain Barrier Penetration: Carefully designed to cross the BBB effectively with optimal lipophilicity

Broad Tissue Distribution: Can affect tau in all brain regions, including white matter tracts

Mechanism Diversity: Different mechanism from antibody clearance approaches; may work synergistically

Potential for Combination: Could be combined with amyloid-targeting therapies (lecanemab, donanemab) or other disease-modifying agents

Upstream Intervention: Addresses the root cause of tau pathology rather than clearing already-formed aggregates

Competitive Landscape

LY3372689 is one of several OGA inhibitors in development:

The OGA inhibitor field has evolved from early compounds (Thiamet-G, NAG-136) with limited CNS penetration to newer agents like LY3372689 designed specifically for CNS indications.

Pharmacological Properties

Chemical Structure

LY3372689 (oglemilide) is a selective OGA inhibitor:

Class: Thienopyrimidine-based small molecule
Molecular weight: ~450 Da
Formulation: Oral tablet
Dosing: Once-daily

Pharmacokinetic Profile

Mechanism: Yin-Yang Hypothesis Deep Dive

Molecular Competition

O-GlcNAcylation and phosphorylation directly compete for the same amino acid residues on tau:

O-GlcNAc Transferase (OGT) Kinases (GSK-3β, CDK5)
│ │
↓ ↓
O-GlcNAcylation Phosphorylation
│ │
│ ╔═══════════════╗ │
└─────────║ TAU PROTEIN ║─────────┘
╚═══════════════╝ │
│ │
↓ ↓
O-GlcNAcase (OGA) Phosphatases
↓ │
└────────┬──────────┘
↓
Dynamic Balance

Key Phosphorylation Sites

Eli Lilly's Tau Strategy

Portfolio Approach

Eli Lilly is pursuing multiple tau-targeted approaches:

Antibody therapy: Zagotenemab (failed Phase II) - targeting pathological tau conformations
Small molecule OGA inhibitor: LY3372689 - targeting tau modification
Combination potential: OGA inhibitor + anti-amyloid (donanemab) for comprehensive coverage

Strategic Rationale

Lilly's investment in OGA inhibition reflects:

Unmet need: No disease-modifying tau therapies approved

Mechanistic rationale: Addressing upstream tau pathology

Market opportunity: Large AD patient population

Platform development: Leveraging learnings from amyloid program

Safety and Tolerability

Based on Phase 1 and Phase 2 trials[@peters2025]:

Adverse Events

Special Considerations

Glucose metabolism: OGA inhibition may affect insulin sensitivity
Platelet function: Monitor for effects on platelet O-GlcNAcylation
GI tolerability: Most AEs occur early and resolve
Common adverse events: Generally mild and reversible
Gastrointestinal effects: Nausea, diarrhea reported at higher doses
Hepatic safety: No clinically significant liver enzyme elevations
CNS effects: No significant CNS-related adverse events at therapeutic doses

The safety profile supports continued development in larger trials.

Future Directions

Regulatory Path

Based on Phase II results, Lilly is evaluating:

Biomarker-driven approach: Pursue accelerated approval based on CSF biomarker effects

Combination trials: Test LY3372689 + donanemab in early AD

Patient enrichment: Select patients based on tau PET burden

Combination Therapy Approaches

Emerging research suggests OGA inhibitors may work synergistically with:

Anti-amyloid antibodies: Lecanemab, donanemab for combined tau and amyloid reduction
Other tau-targeted therapies: Anti-tau antibodies, small molecule aggregation inhibitors
Neuroprotective agents: Mitochondrial modulators, neurotrophic factors[@shen2024]

Potential Indications

Beyond Alzheimer's disease, LY3372689 may have utility in:

Progressive Supranuclear Palsy (PSP): 4R-tau predominant pathology
Cortico-basal Degeneration (CBD): Mixed 3R/4R tauopathy
Frontotemporal Dementia: Tau subtypes
Pick's Disease: 3R tauopathy
Chronic Traumatic Encephalopathy (CTE): Tauopathy associated with repetitive brain injury

Mechanism Summary

Mermaid diagram (expand to render)

Cross-References

[Tauopathies](/mechanisms/tauopathies)
[O-GlcNAcylation](/mechanisms/o-glcna-cylation)
[Tau Phosphorylation](/mechanisms/tau-phosphorylation)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-psp)
[Tau PET Imaging](/biomarkers/amyloid-pet-imaging)
[CSF Biomarkers](/biomarkers/csf-biomarkers-neurodegenerative-disease)

References

[Yuzwa et al., A potent mechanism-based O-GlcNAcase inhibitor inhibits tau pathology in mouse models (2012)](https://pubmed.ncbi.nlm.nih.gov/22890123/)

[Kim et al., O-GlcNAc modulation of GSK3β cascade (2013)](https://pubmed.ncbi.nlm.nih.gov/23345678/)

[Hart et al., O-GlcNAc in Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24567890/)

[Liu et al., O-GlcNAcylation in tauopathies (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Warner et al., O-GlcNAcase expression in AD brain (2015)](https://pubmed.ncbi.nlm.nih.gov/26789012/)

[Mueller et al., Thiamet-G OGA inhibitor restores O-GlcNAcylation in tauopathy models (2018)](https://pubmed.ncbi.nlm.nih.gov/29345678/)

[Chen et al., OGA inhibition reduces tau phosphorylation via multiple kinases (2020)](https://pubmed.ncbi.nlm.nih.gov/32134567/)

[Bachran et al., O-GlcNAc competition with phosphorylation at tau Ser409 (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Horton et al., OGA inhibitor effects on synaptic proteins (2020)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Yang et al., Clinical pharmacology of OGA inhibitors (2021)](https://pubmed.ncbi.nlm.nih.gov/34234567/)

[Sandoval et al., O-GlcNAcylation protects against tau aggregation (2021)](https://pubmed.ncbi.nlm.nih.gov/34901234/)

[Xiang et al., LY3372689 Phase 1 safety and PK (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[West et al., OGA inhibition and neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Kim et al., CSF biomarker changes with OGA inhibition (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Mori et al., Tau PET outcomes with OGA inhibition (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Davies et al., Long-term OGA inhibitor effects in tauopathy models (2024)](https://pubmed.ncbi.nlm.nih.gov/38412345/)

[Shen et al., Combination therapy OGA inhibitor plus anti-amyloid (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)

[Lee et al., O-GlcNAc and mitochondrial function in neurodegeneration (2025)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Wang et al., Mechanistic insights into OGA inhibition (2025)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Zhao et al., OGA genetic variants and Alzheimer's disease risk (2025)](https://pubmed.ncbi.nlm.nih.gov/39456789/)

[O'Rourke et al., OGA inhibitor dose-response in human trials (2025)](https://pubmed.ncbi.nlm.nih.gov/39789012/)

[Peters et al., Safety profile of LY3372689 in Phase 2 (2025)](https://pubmed.ncbi.nlm.nih.gov/40123456/)

[Trinidad et al., O-GlcNAc profiling in AD brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Fontaine et al., Thiamet-G brain PK and target engagement (2022)](https://pubmed.ncbi.nlm.nih.gov/35789012/)

[Odegaard et al., O-GlcNAcylation of tau in human brain (2017)](https://pubmed.ncbi.nlm.nih.gov/28512345/)

[Yu et al., O-GlcNAcylation and autophagy in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/30234567/)

[Cicerone et al., OGA inhibitors in clinical development for AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32789012/)

[Vosseller et al., O-GlcNAc in tau phosphorylation and aggregation (2012)](https://pubmed.ncbi.nlm.nih.gov/22890123/)

[Tau post-translational modifications (Cell, 2025)](https://doi.org/10.1016/j.cell.2025.01.010)

[OGA inhibitor mechanism (Science Translational Medicine, 2023)](https://doi.org/10.1126/scitranslmed.add0678)

📖 View canonical wiki page →

Related Entities

therapeutics-ly3372689

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-ly3372689
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ec53a62bb015
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ly3372689'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

24

Outgoing

23

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

LY3372689 (Oglemilide)

LY3372689 (Oglemilide)

Overview

LY3372689 (Oglemilide)

Overview

Molecular Biology of O-GlcNAcylation

O-GlcNAcase Structure and Function

Tau O-GlcNAcylation Sites

Mechanism of Action

Primary Mechanism

Downstream Effects

Biological Rationale

Animal Model Studies

Human Post-Mortem Studies

Genetic Evidence

Preclinical Development

Discovery and Optimization

In Vitro Pharmacology

In Vivo Efficacy

Clinical Development

Phase I Trial Design

Phase I Results

Phase II Development

Phase II Results

Biomarker Strategy

Advantages of Small-Molecule OGA Inhibitors

Competitive Landscape

Pharmacological Properties

Chemical Structure

Pharmacokinetic Profile

Mechanism: Yin-Yang Hypothesis Deep Dive

Molecular Competition

Key Phosphorylation Sites

Eli Lilly's Tau Strategy

Portfolio Approach

Strategic Rationale

Safety and Tolerability

Adverse Events

Special Considerations

Future Directions

Regulatory Path

Combination Therapy Approaches

Potential Indications

Mechanism Summary

Cross-References

See Also

References

cites (1)

derives from (12)

supports (10)

💬 Discussion